EUCTR2010-020730-26-FR进行中（未招募）1 期
A PLACEBO-CONTROLLED, ESCALATING DOSE, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES
Pfizer Inc.235 East 42nd Street, New York, NY 100170 个研究点目标入组 65 人开始时间: 2010年7月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- •1. Male and female epilepsy patients, age 1 month (44 weeks gestational age) to 16 years inclusive, with a minimum body weight of 3.5 kg.
- •2. Seizures classified as simple partial, complex partial, or partial becoming secondarily generalized, according to the International League Against Epilepsy (ILAE) Classification of Seizures. Partial onset seizures must be diagnosed in either of two ways:
- •a. Clinical observation of partial seizures with focal semiology confirmed by and consistent with the localization of either:
- •Focal epileptiform abnormality on EEG within the last 2 years, or
- •Focal abnormality on imaging; or
- •b. Seizure recorded by EEG monitoring which fulfills the ILAE criteria for EEG seizure type within the last 2 years.
- •3.Must have a partial seizure frequency of at least 1 seizure per 28 day month prior to enrollment.
- •4. Currently receiving a stable dosage of 1 to 3 antiepileptic drugs (stable within 7 days of screening), with blood levels within typically accepted therapeutic range. Benzodiazepine medication used at a stable dosage and frequency for rescue treatment will be considered one of the concurrent antiepileptic treatments.
- •5. A head CT scan with contrast, or MRI of the brain (at any time prior to study participation), demonstrating no abnormality that is likely to be progressive, and no clinical evidence of a progressive abnormality.
- •6. A 12 lead ECG at screening without significant abnormal findings.
- •7. Subjects and parents/legal guardians must be thought to be compliant and able to follow the investigator’s instructions. They must be able to visit the clinic on schedule and be both cooperative and reliable.
- •8. Parents/legal guardians must give written informed consent prior to the start of the study. Consent should be obtained from both (if available) of the child’s legal representatives (parents or guardians). Whenever the minor child is able to give assent, the minor’s assent must be obtained.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will not be included in the trial:
- •1. A current diagnosis of febrile seizures, or seizures related to an ongoing acute medical illness. Any febrile seizures within 6 months of screening.
- •2. Primary (eg, absence epilepsy) or secondary (eg, Lennox-Gastaut syndrome, infantile spasms, myoclonic or atonic epilepsies) generalized epilepsy.
- •3. Seizures related to drugs, alcohol, or acute medical illness.
- •4. Any change in AED regimen during the last 7 days prior to screening.
- •5. Progressive structural CNS lesion or a progressive encephalopathy. Progressive inborn errors of metabolism.
- •6. Known or suspected chronic hematologic, hepatic or renal disease (AST and ALT above 3 times the upper limit of normal; or bilirubin, BUN, or creatinine above 2 times the upper limit of normal within the previous 6 months for infants, children and adolescents aged 6 months or more, or at any postnatal period for infants younger than 6 months).
- •7. Known or suspected white blood cell counts below 3000/mm3; absolute neutrophil counts of less than 1500/mm3, or platelet counts of less than 100x103/mm3.
- •8. Estimated creatinine clearance (ClCR) <80 mL/min/1.73m2. The Cockcroft Gault equation normalized for body surface area will be used for estimating creatinine clearance for ages 12-16 years. Creatinine clearance (in units of ml/min/1.73m2) will be estimated for the younger children using the following equations:
- •ClCR = 0.45×length (cm)/serum creatinine (mg/dL), for infants 1 to <12 months old;
- •ClCR = 0.55×length (cm)/serum creatinine (mg/dL), for children 1 to <12 years old.
- •9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial.
- •10. Pregnant or nursing females (females age 10 or greater, or who are menarchal must have a negative pregnancy test); menarchal females of childbearing potential who are unwilling or unable to use an acceptable method of contraception, as outlined in the protocol, from at least 14 days prior to the first dose of trial medication until completion of follow-up procedures.
- •11.Any condition possibly affecting drug absorption (eg, gastrectomy).
- •12.Taking any non-antiepileptic (non-AED) medication that could alter the effectiveness of the patient’s medication, response, seizure frequency or characteristics. The use of gabapentin, felbamate, vigabatrin, or agents with central nervous system activity within 1 week of screening, and throughout the study, is prohibited.
- •13. Taking or have taken any other investigational drug within the last 30 days prior to screening.
- •14. A positive urine drug screen for non-therapeutic drugs (subjects testing positive will not be randomized).
- •15. Unwilling or unable to comply with the Lifestyle Guidelines.
- •16. Use of tobacco- or nicotine-containing products.
- •17. Previous use of pregabalin.
- •18. History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •19. Not reasonably expected to complete the trial.
研究者
相似试验
已完成
不适用
A DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SUBCUTANEOUS DOSE OF SHK-186 IN HEALTHY SUBJECTSDisorder in which the body makes antibodies against bodys own proteins10003816NL-OMON36904Kineta One56
未知
不适用
A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, MULTI-CENTRE TRIAL OF QAW039 (1-450 mg p.o) TO INVESTIGATE THE EFFECT ON FEV1 AND ACQ IN PATIENTS WITH MODERATE-TO-SEVERE, PERSISTENT, ALLERGIC, ASTHMA, INADEQUATELY CONTROLLED WITH ICS THERAPYPER-106-11OVARTIS BIOSCIENSES PERU S.A.,53
进行中（未招募）
不适用
A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDYOF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTSWITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.EUCTR2004-000415-26-ITSIGMA-TA440
进行中（未招募）
不适用
ot applicableEUCTR2011-002665-38-GBAlmirall S.A.110
进行中（未招募）
1 期
A clinical study to assess the benefits of aclidinium bromide/formoterol fumarate (active treatment) compared with placebo (comparator) in lung volumes, exercise capacity and physical activity after 8-weeks of treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD). The study is randomised (equal chance of receiving active treatment or comparator) and double blind (neither patients nor the study doctor will know the treatment).Chronic obstructive pulmonary disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-005318-50-HUAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden268